Zion Pharma Raises $20 Million in Series A+ Financing

According to VCBeat, Suzhou Zanrong Pharmaceutical Technology Co., Ltd. ("Zion Pharma") announced the completion of a $20 million Series A+ financing. 

The proceeds from the latest round will be used to conduct the phase I clinical trials of Zion Pharma's core projects in both China and the United States, promote the IND application and clinical screening of drug candidates of other pipelines. In addition, the company will also develop new projects, expand the diversified pipeline and its internationalization.

The investment was led by Sherpa Venture Capital and Qiming Venture Partners with participation from Med-Fine Capital. Among them, Qiming Venture Partners and Med-Fine Capital are the existing investors of Zion Pharma

Zion Pharma focuses on small molecule antitumor drugs that provide solutions to unmet medical needs and benefit patients around the world. The company's core team has rich pharmaceutical experience and high scientific standard. Since the establishment of Zion Pharma, two clinical drug candidates have been selected and two international patents have been applied. 

By taking advantage of the unique advantages of drug metabolism and pharmacokinetics (DMPK), Zion Pharma designs small-molecule anti-tumor drugs from a differentiated perspective to solve the core problems of drug development. 

Founded in 2018 and is headquartered in Beijing, China, Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where the company has established robust portfolio sources, lasting value-adding cooperation and relationships, as well as mature all-cycle services with key resources.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.